These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11042688)

  • 1. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.
    Kim R; Beck WT
    Cancer Res; 1994 Sep; 54(18):4958-66. PubMed ID: 8069863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
    Goldwasser F; Bae I; Fornace AJ; Pommier Y
    Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase.
    DeHaan RD; Yazlovitskaya EM; Persons DL
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):383-8. PubMed ID: 11761456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.
    Chen M; Beck WT
    Oncol Res; 1995; 7(2):103-11. PubMed ID: 7579726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
    Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
    Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
    Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
    O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
    Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb.
    Ameyar M; Shatrov V; Bouquet C; Capoulade C; Cai Z; Stancou R; Badie C; Haddada H; Chouaib S
    Oncogene; 1999 Sep; 18(39):5464-72. PubMed ID: 10498900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
    Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
    Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
    Chen M; Beck WT
    Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the GADD45 response to ionizing radiation in WI-L2-NS cells, a p53 mutant cell line.
    Carrier F; Bae I; Smith ML; Ayers DM; Fornace AJ
    Mutat Res; 1996 Jun; 352(1-2):79-86. PubMed ID: 8676920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
    Wolverton JS; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation.
    Chin PL; Momand J; Pfeifer GP
    Oncogene; 1997 Jul; 15(1):87-99. PubMed ID: 9233781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.